The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Maslov D.E.

Novosibirsk State Univeristy

Osipov I.D.

Novosibirsk State Univeristy

Vasikhovskaya V.A.

Novosibirsk State Univeristy

Zabelina D.S.

Novosibirsk State Univeristy

Meshcheryakov N.I.

Novosibirsk State Univeristy

Kartashov M.Yu.

Novosibirsk State Univeristy;
State Research Center Virology and Biotechnology «Vector» Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing of Russia World-Class Genomic Research Center for Biological Safety and Technological Independence

Romanov S.E.

Novosibirsk State Univeristy

Netesov S.V.

Novosibirsk State University

Respiratory-syncitial virus: biology, genetic diversity and perspective control preparations

Authors:

Maslov D.E., Osipov I.D., Vasikhovskaya V.A., Zabelina D.S., Meshcheryakov N.I., Kartashov M.Yu., Romanov S.E., Netesov S.V.

More about the authors

Journal: Molecular Genetics, Microbiology and Virology. 2024;42(1): 16‑24

DOI: 10.17116/molgen20244201116

Read: 1667 times

Download PDF (RU)
Contact the author
Table of contents

RESPIRATORY-SYNCITIAL VIRUS: BIOLOGY, GENETIC DIVERSITY AND PERSPECTIVE CONTROL PREPARATIONS
RESPIRATORY-SYNCITIAL VIRUS: BIOLOGY, GENETIC DIVERSITY AND PERSPECTIVE CONTROL PREPARATIONS

To cite this article:

Maslov DE, Osipov ID, Vasikhovskaya VA, et al. . Respiratory-syncitial virus: biology, genetic diversity and perspective control preparations. Molecular Genetics, Microbiology and Virology. 2024;42(1):16‑24. (In Russ.)
https://doi.org/10.17116/molgen20244201116

Подписка 2026 Молекулярная генетика, микробиология и вирусология (Molecular Genetics, Microbiology and Virology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Study of the influence of nucleotide sequence opti­mization of the target gene on the immu­nogenicity of a reco­mbinant adenovirus vector. Mole­cular Gene­tics, Microbiology and Viro­logy. 2024;(4):43-48
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
Chro­nic obstructive pulmonary disease (COPD 2024). Clinical guidelines (short version). Journal of Respiratory Medi­cine. 2025;(2):5-16
Community-acquired pneumonia in adults. Clinical guidelines 2024 (short version). Journal of Respiratory Medi­cine. 2025;(3):6-18
Abstract:

Human respiratory syncytial virus (RSV) is an RNA virus of the Pneumoviridae family and is a common causative agent of acute respiratory infections. Infection with this virus is often severe and can result in fatalities and chronic complications, particularly in high-risk groups such as children under the age of 5 and elderly individuals over 65 years old. This review presents the latest data on the taxonomy, virion structure, and genome map of RSV, as well as its role in the etiology of acute respiratory diseases. We have analyzed over 100 publications on RSV genotyping in different parts of the world including Russia published between 2015 and 2023. The genetic composition of RSV isolates in Russia is similar to that in other regions of the world, predominantly represented by genotypes ON1 and BA9. The development of effective vaccines is crucial for successful disease control. The review summarizes global advances in the development of interventions against RSV, emphasizing promising treatments currently undergoing clinical trials and the ones that have recently been approved. Similar interventions (vaccines) are yet to be developed in Russia, but the similarities in genetic composition of RSV in Russia and worldwide offer hope for the rapid development of domestic vaccines against this infection.

Keywords:

lower respiratory tract infections
respiratory syncytial virus
pneumoviruses
vaccines
genetic variability
therapeutics

Authors:

Maslov D.E.

Novosibirsk State Univeristy

Osipov I.D.

Novosibirsk State Univeristy

Vasikhovskaya V.A.

Novosibirsk State Univeristy

Zabelina D.S.

Novosibirsk State Univeristy

Meshcheryakov N.I.

Novosibirsk State Univeristy

Kartashov M.Yu.

Novosibirsk State Univeristy;
State Research Center Virology and Biotechnology «Vector» Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing of Russia World-Class Genomic Research Center for Biological Safety and Technological Independence

Romanov S.E.

Novosibirsk State Univeristy

Netesov S.V.

Novosibirsk State University

Received:

08.01.2024

Accepted:

15.02.2024

Close metadata

References:

  1. Morris JA, Blount RE, Savage RE. Recovery of Cytopathogenic Agent from Chimpanzees with Goryza. Exp Biol Med. 1956;92(3):544-549.  https://doi.org/10.3181/00379727-92-22538
  2. Chanock R, Roizman B, Myers R, Finberg L, Roizman B, Myers R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). Am J Epidemiol. 1957;66(3):291-300.  https://doi.org/10.1093/oxfordjournals.aje.a119901
  3. Chanock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). Am J Epidemiol. 1957;66(3):291-300.  https://doi.org/10.1093/oxfordjournals.aje.a119902
  4. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958.  https://doi.org/10.1016/S0140-6736(17)30938-8
  5. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The Burden of Respiratory Syncytial Virus Infection in Young Children. N Engl J Med. 2009;360(6):588-598.  https://doi.org/10.1056/NEJMoa0804877
  6. Srikantiah P, Vora P, Klugman KP. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies. Clin Infect Dis. 2021;73(suppl 3):S177-S179. https://doi.org/10.1093/cid/ciab486
  7. Sommer C. Risk Factors for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection. Open Microbiol J. 2011;5(1):144-154.  https://doi.org/10.2174/1874285801105010144
  8. Rosas-Salazar C, Chirkova T, Gebretsadik T, Chappell JD, Peebles RS, Dupont WD, et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet. 2023;401(10389):1669-1680. https://doi.org/10.1016/S0140-6736(23)00811-5
  9. Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, et al. Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection. J Infect Dis. 2020;222(8):1298-1310. https://doi.org/10.1093/infdis/jiaa361
  10. Ackerson B, Tseng HF, Sy LS, Solano Z, Slezak J, Luo Y, et al. Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults. Clin Infect Dis. 2019;69(2):197-203.  https://doi.org/10.1093/cid/ciy991
  11. Kurskaya O, Ryabichenko T, Leonova N, Shi W, Bi H, Sharshov K, et al. Viral etiology of acute respiratory infections in hospitalized children in Novosibirsk City, Russia (2013—2017). Othumpangat S, ed. PLoS One. 2018;13(9):e0200117. https://doi.org/10.1371/journal.pone.0200117
  12. Kurskaya OG, Prokopyeva EA, Sobolev IA, Solomatina M V, Saroyan TA, Dubovitskiy NA, et al. Changes in the Etiology of Acute Respiratory Infections among Children in Novosibirsk, Russia, between 2019 and 2022: The Impact of the SARS-CoV-2 Virus. Viruses. 2023;15(4):934.  https://doi.org/10.3390/v15040934
  13. Sominina A, Danilenko D, Komissarov A, Pisareva M, Musaeva T, Bakaev M, et al. Age-Specific Etiology of Severe Acute Respiratory Infections and Influenza Vaccine Effectivity in Prevention of Hospitalization in Russia, 2018—2019 Season. J Epidemiol Glob Health. 2021;11(4):413-425.  https://doi.org/10.1007/s44197-021-00009-1
  14. Current ICTV Taxonomy Release. Accessed October 6, 2023. https://ictv.global/taxonomy
  15. Collins PL, Fearns R, Graham BS. Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease. In:2013;3-38.  https://doi.org/10.1007/978-3-642-38919-1_1
  16. Blanchard EL, Braun MR, Lifland AW, Ludeke B, Noton SL, Vanover D, et al. Polymerase-tagged respiratory syncytial virus reveals a dynamic rearrangement of the ribonucleocapsid complex during infection. Whelan SPJ, ed. PLOS Pathog. 2020;16(10):e1008987. https://doi.org/10.1371/journal.ppat.1008987
  17. Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17(4):233-245.  https://doi.org/10.1038/s41579-019-0149-x
  18. McLellan JS, Ray WC, Peeples ME. Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins. In: 2013;83-104.  https://doi.org/10.1007/978-3-642-38919-1_4
  19. Yu JM, Fu YH, Peng XL, Zheng YP, He JS. Genetic diversity and molecular evolution of human respiratory syncytial virus A and B. Sci Rep. 2021;11(1):12941. https://doi.org/10.1038/s41598-021-92435-1
  20. Jha A, Jarvis H, Fraser C, Openshaw PJM. Respiratory Syncytial Virus. In: SARS, MERS and Other Viral Lung Infections. 2016. https://www.ncbi.nlm.nih.gov/pubmed/20399493
  21. Feng Z, Xu L, Xie Z. Receptors for Respiratory Syncytial Virus Infection and Host Factors Regulating the Life Cycle of Respiratory Syncytial Virus. Front Cell Infect Microbiol. 2022;12.  https://doi.org/10.3389/fcimb.2022.858629
  22. Gilman MSA, Castellanos CA, Chen M, Ngwuta JO, Goodwin E, Moin SM, et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol. 2016;1(6). https://doi.org/10.1126/sciimmunol.aaj1879
  23. Goodwin E, Gilman MSA, Wrapp D, Chen M, Ngwuta JO, Moin SM, et al. Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation. Immunity. 2018;48(2):339-349.e5.  https://doi.org/10.1016/j.immuni.2018.01.005
  24. Ramaekers K, Rector A, Cuypers L, Lemey P, Keyaerts E, Van Ranst M. Towards a unified classification for human respiratory syncytial virus genotypes. Virus Evol. 2020;6(2). https://doi.org/10.1093/ve/veaa052
  25. Langedijk AC, Harding ER, Konya B, Vrancken B, Lebbink RJ, Evers A, et al. A systematic review on global RSV genetic data: Identification of knowledge gaps. Rev Med Virol. 2022;32(3). https://doi.org/10.1002/rmv.2284
  26. Eshaghi A, Duvvuri VR, Lai R, Nadarajah JT, Li A, Patel SN, et al. Genetic Variability of Human Respiratory Syncytial Virus A Strains Circulating in Ontario: A Novel Genotype with a 72 Nucleotide G Gene Duplication. Khudyakov YE, ed. PLoS One. 2012;7(3):e32807. https://doi.org/10.1371/journal.pone.0032807
  27. Shobugawa Y, Saito R, Sano Y, Zaraket H, Suzuki Y, Kumaki A, et al. Emerging Genotypes of Human Respiratory Syncytial Virus Subgroup A among Patients in Japan. J Clin Microbiol. 2009;47(8):2475-2482. https://doi.org/10.1128/JCM.00115-09
  28. Krivitskaya V, Komissarova K, Pisareva M, Sverlova M, Fadeev A, Petrova E, et al. Respiratory Syncytial Virus G Protein Sequence Variability among Isolates from St. Petersburg, Russia, during the 2013—2014 Epidemic Season. Viruses. 2021;13(1):119.  https://doi.org/10.3390/v13010119
  29. Prokopyeva EA, Kurskaya OG, Solomatina MV, Sobolev IA, Saroyan TA, Dubovitskiy NA, et al. Virological and genetic characteristics of human respiratory syncytial viruses isolated in Russia, 2017—2018. J Infect Dev Ctries. 2023;17(02):251-259.  https://doi.org/10.3855/jidc.17462
  30. Hause AM, Henke DM, Avadhanula V, Shaw CA, Tapia LI, Piedra PA. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. Tregoning JS, ed. PLoS One. 2017;12(4):e0175792. https://doi.org/10.1371/journal.pone.0175792
  31. Tapia LI, Shaw CA, Aideyan LO, Jewell AM, Dawson BC, Haq TR, Piedra PA. Gene Sequence Variability of the Three Surface Proteins of Human Respiratory Syncytial Virus (HRSV) in Texas. Varga SM, ed. PLoS One. 2014;9(3):e90786. https://doi.org/10.1371/journal.pone.0090786
  32. Johnson PR, Olmsted RA, Prince GA, Murphy BR, Alling DW, Walsh EE, Collins PL. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol. 1987;61(10):3163-3166. https://doi.org/10.1128/jvi.61.10.3163-3166.1987
  33. Broughton S, Greenough A. Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity. Expert Opin Pharmacother. 2003;4(10):1801-1808. https://doi.org/10.1517/14656566.4.10.1801
  34. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422-434.  https://doi.org/10.1093/oxfordjournals.aje.a120955
  35. Acosta PL, Caballero MT, Polack FP. Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease. Papasian CJ, ed. Clin Vaccine Immunol. 2016;23(3):189-195.  https://doi.org/10.1128/CVI.00609-15
  36. Ribavirin aerosol approved for severe cases of RSV in infants and young children. FDA Drug Bull. 1986;16(1):7.  https://www.ncbi.nlm.nih.gov/pubmed/3732682
  37. Hayden FG, Whitley RJ. Respiratory Syncytial Virus Antivirals: Problems and Progress. J Infect Dis. 2020;222(9):1417-1421. https://doi.org/10.1093/infdis/jiaa029
  38. Ark Biopharmaceutical Announces NMPA Acceptance and Priority Review of New Drug Application for Ziresovir for Treatment of RSV Infection. Accessed December 4, 2023. https://www.arkbiosciences.com/en_2022n/114
  39. Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023;21(11):734-749.  https://doi.org/10.1038/s41579-023-00919-w
  40. Sandritter TL, Kraus DM. Respiratory syncytial virus-immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: Part I. J Pediatr Heal Care. 1997;11(6):284-291.  https://doi.org/10.1016/S0891-5245(97)90086-9
  41. Brady MT, Byington CL, Davies HD, Edwards KM, Jackson MA, Maldonado YA, et al. Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics. 2014;134(2):e620-e638. https://doi.org/10.1542/peds.2014-1666
  42. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-540.  https://doi.org/10.1067/S0022-3476(03)00454-2
  43. Wasserman RL, Greener BN, Mond J. RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations. Expert Rev Clin Immunol. 2017;13(12):1107-1119. https://doi.org/10.1080/1744666X.2017.1389647
  44. Ruckwardt TJ. The road to approved vaccines for respiratory syncytial virus. npj Vaccines. 2023;8(1):138.  https://doi.org/10.1038/s41541-023-00734-7
  45. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020;383(5):415-425.  https://doi.org/10.1056/NEJMoa1913556
  46. Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388). https://doi.org/10.1126/scitranslmed.aaj1928
  47. Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised. Lancet Child Adolesc Heal. 2023;7(3):180-189.  https://doi.org/10.1016/S2352-4642(22)00321-2
  48. Mazur NI, Terstappen J, Baral R, Bardají A, Beutels P, Buchholz UJ, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023;23(1):e2-e21.  https://doi.org/10.1016/S1473-3099(22)00291-2
  49. Karron RA, Atwell JE, McFarland EJ, Cunningham CK, Muresan P, Perlowski C, et al. Live-attenuated Vaccines Prevent Respiratory Syncytial Virus—associated Illness in Young Children. Am J Respir Crit Care Med. 2021;203(5):594-603.  https://doi.org/10.1164/rccm.202005-1660OC
  50. Billard MN, Bont LJ. Live-attenuated Respiratory Syncytial Virus Vaccines: Time for the Next Step. Am J Respir Crit Care Med. 2021;203(5):538-539.  https://doi.org/10.1164/rccm.202009-3431ED
  51. Stuart AS V, Virta M, Williams K, Seppa I, Hartvickson R, Greenland M, et al. Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18—50 Years and RSV-Seropositive Children 12—24 Months. J Infect Dis. 2022;227(1):71-82.  https://doi.org/10.1093/infdis/jiac407
  52. Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, Sánchez MG, et al. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. J Infect Dis. 2023;228(3):299-310.  https://doi.org/10.1093/infdis/jiad024
  53. Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023;388(16):1451-1464. https://doi.org/10.1056/NEJMoa2216480
  54. FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants | FDA. Accessed December 4, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants
  55. U.S. FDA Approves ABRYSVO, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults | Pfizer.
  56. US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults | GSK. 
  57. Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults — Icosavax, Inc. Accessed December 4, 2023. https://ir.icosavax.com/news-releases/news-release-details/icosavax-initiates-phase-1-trial-ivx-a12-against-rsv-and-hmpv
  58. Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, et al. Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults. N Engl J Med. 2023;388(7):609-620.  https://doi.org/10.1056/NEJMoa2207566
  59. Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults. Accessed December 4, 2023. https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-mRNA-1345-an-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Has-Met-Primary-Efficacy-Endpoints-in-Phase-3-Trial-in-Older-Adults/default.aspx
  60. Brakel KA, Binjawadagi B, French-Kim K, Watts M, Harder O, Ma Y, et al. Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model. Vaccine. 2021;39(47):6817-6828. https://doi.org/10.1016/j.vaccine.2021.10.042
  61. World regions according to the World Bank. https://ourworldindata.org/grapher/world-regions-according-to-the-world-bank
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.